Biopharmaceutical company focused on developing therapies for central nervous system disorders.
Sage Therapeutics, Inc., a pioneering biopharmaceutical firm, specializes in advancing treatments for central nervous system disorders. At the forefront of its portfolio is ZULRESSO, an intravenous brexanolone formulation designed to alleviate postpartum depression (PPD) in adults. The company's robust pipeline includes zuranolone, a neuroactive steroid currently undergoing Phase III clinical trials for PPD, major depressive disorder, treatment-resistant depression, generalized anxiety disorder, and bipolar depression.
Further expanding its therapeutic offerings, Sage Therapeutics is progressing SAGE-324, a compound in Phase II clinical trials targeting essential tremors, with completed Phase I trials for epilepsy and Parkinson's disease. Additionally, the company is advancing SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trials for depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain.
In its strategic initiatives, Sage Therapeutics collaborates with Shionogi & Co., Ltd. for the development and commercialization of zuranolone across Japan, Taiwan, and South Korea. Additionally, the company has entered a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products, enhancing its global reach and therapeutic impact.
Originally incorporated as Sterogen Biopharma, Inc. and rebranded in September 2011, Sage Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. With a dedicated focus on pioneering neuroscience treatments, the company continues to drive innovation in CNS disorders, striving to improve patient outcomes through its comprehensive approach to drug development and strategic partnerships.